These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings. Tunis SL. Appl Health Econ Health Policy; 2011 Nov 01; 9(6):351-65. PubMed ID: 21892840 [Abstract] [Full Text] [Related]
5. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain. Tunis SL, Willis WD, Foos V. Curr Med Res Opin; 2010 Jan 01; 26(1):163-75. PubMed ID: 19919377 [Abstract] [Full Text] [Related]
6. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ. Curr Med Res Opin; 2007 Mar 01; 23(3):609-22. PubMed ID: 17355742 [Abstract] [Full Text] [Related]
7. Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. Roze S, Isitt J, Smith-Palmer J, Javanbakht M, Lynch P. Diabetes Care; 2020 Oct 01; 43(10):2411-2417. PubMed ID: 32647050 [Abstract] [Full Text] [Related]
8. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents. Pollock RF, Valentine WJ, Goodall G, Brändle M. Swiss Med Wkly; 2010 Oct 01; 140():w13103. PubMed ID: 21110238 [Abstract] [Full Text] [Related]
9. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid. Frank J, Son D, Szafranski K, Poon Y. J Manag Care Spec Pharm; 2024 Sep 01; 30(9):917-928. PubMed ID: 39109990 [Abstract] [Full Text] [Related]
11. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M, PROactive Study Group. Diabet Med; 2007 Sep 01; 24(9):982-1002. PubMed ID: 17593245 [Abstract] [Full Text] [Related]
14. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off. Findley LJ, Lees A, Apajasalo M, Pitkänen A, Turunen H. Curr Med Res Opin; 2005 Jul 01; 21(7):1005-14. PubMed ID: 16004667 [Abstract] [Full Text] [Related]
19. Cost-utility of real-time continuous glucose monitoring versus self-monitoring of blood glucose in people with insulin-treated Type II diabetes in France. Alshannaq H, Pollock RF, Joubert M, Ahmed W, Norman GJ, Lynch PM, Roze S. J Comp Eff Res; 2024 Mar 01; 13(3):e230174. PubMed ID: 38294332 [Abstract] [Full Text] [Related]